Extended Data Fig. 2: Median LDL cholesterol percent changes in subgroups (demographics). | Nature Medicine

Extended Data Fig. 2: Median LDL cholesterol percent changes in subgroups (demographics).

From: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

Extended Data Fig. 2

Least squares mean (95% confidence intervals) treatment group differences in percent changes in LDL cholesterol with obicetrapib at day 84 in patient subgroups of demographics, medical history and statin use. Apo, apolipoprotein; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Sample sizes vary by subgroup. All data represent biological replicates (individual patients with heterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy).

Back to article page